Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Earnings for Zymeworks Inc. (ZYME)
Earnings in 2023 (TTM): $-119,242,000
According to Zymeworks Inc.'s latest financial reports the company's current earnings (TTM) are $-119,242,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Zymeworks Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-119,242,000 | $-118,674,000 |
| 2022 | $135.23 M | $124.34 M |
| 2021 | $-212,359,000 | $-211,843,000 |
| 2020 | $-180,123,000 | $-180,552,000 |
| 2019 | $-146,019,000 | $-145,437,000 |
| 2018 | $-34,385,000 | $-36,556,000 |
| 2017 | $-9,962,000 | $-10,406,000 |
| 2016 | $-38,884,000 | $-33,809,000 |
| 2015 | $-19,136,000 | $-19,170,000 |
| 2014 | $-12,942,000 | $-12,942,000 |